ReviewInternational journal of biological sciences2023
Active Ingredients from Chinese Medicine for Combination Cancer Therapy.
Review in International journal of biological sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of Chinese medicine injection combined with concurrent chemoradiotherapy in the treatment of esophageal cancer: a Bayesian network meta-analysis.Frontiers in medicine · 2025Pooled it
- The Natural Flavonoid Pectolinarigenin Targets On-Canonical NF-κB Pathway to Inhibit Esophageal Squamous Cell Carcinoma and Enhances Paclitaxel Efficacy.Drug development research · 2026Article
- Tumor Microenvironment-on-a-Chip: Construction and Application in Traditional Chinese Medicine Anti-Tumor Therapy.Biosensors · 2026Review
- Gracillin overcomes osimertinib resistance in NSCLC via dual inhibition of EGFR and Mcl-1.Cancer gene therapy · 2026Article
- Exploration of the multi-component, multi-target, and multi-pathway mechanism ofBiochemistry and biophysics reports · 2026Article
- Article
- Molecular Compatibility in Chinese Medicine for Cancer Treatment and Drug Development: From Traditional Wisdom to Innovative Therapeutics.Chinese journal of integrative medicine · 2026Article
- Ponicidin Inhibits Lung Cancer Progression Through Coordinated Downregulation of Sulfhydryl Antioxidants and TrxR1.Antioxidants (Basel, Switzerland) · 2026Article
- Harmonizing yin and yang, remodeling the microenvironment: the adjuvant potential of Chinese herbal medicine in tumor immunotherapy.Frontiers in oncology · 2026Review
- A Dual-Drug Nanosuspension of Bufalin and Quercetin Exhibits Potent Anti-Hepatocellular Carcinoma ActivityCurrent drug delivery · 2026Article
- Network Pharmacology Analysis and Experimental Verification of Weinaian Capsule for Treating Gastric Cancer.Current pharmaceutical biotechnology · 2026Article
- Targeting cancer with delphinidin: from molecular insights to therapeutic implications.Frontiers in pharmacology · 2026Review
- ABC Transporter Protein-mediated Multidrug Resistance in Breast Cancer and Development of Targeting Strategies.Recent patents on anti-cancer drug discovery · 2026Review
- Astragalin: A promising herbal compound with broad anticancer potential (Review).Oncology letters · 2026Review
- In vitro study on reversible regulation of CAR-T function by Kinsenoside.Molecular biology reports · 2025Article
- Paclitaxel and Cephalomannine Synergistically Induce PANoptosis in Triple-Negative Breast Cancer Through Oxygen-Regulated Cell Death Pathways.Antioxidants (Basel, Switzerland) · 2025Article
- Diallyl disulfide in oncotherapy: molecular mechanisms and therapeutic potentials.Apoptosis : an international journal on programmed cell death · 2025Review
- Global research trends on Chinese patent drugs inducing programmed cell death in cancer: a bibliometric analysis (1998-2024).Discover oncology · 2025Article
- Co-Encapsulation of Multiple Antineoplastic Agents in Liposomes by Exploring Microfluidics.International journal of molecular sciences · 2025Review
- New dimensions of PD-1/PD-L1 inhibitor combination therapy in cancer treatment: current advances and future perspectives.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combination therapy against cancer has gained increasing attention because it can help to target multiple pathways to tackle oncologic progression and improve the limited antitumor effect of single-agent therapy. Chinese medicine has been studied extensively in cancer therapy and proven to be efficacious in many cases due to its wide spectrum of anticancer activities. In this review, we aim to summarize the recent progress of active ingredients from Chinese medicine (AIFCM) in combination with various cancer therapeutic modalities, including chemotherapy, gene therapy, radiotherapy, phototherapy and immunotherapy. In addition to highlighting the potential contribution of AIFCM in combination cancer therapy, we also elucidate the underlying mechanisms behind their synergistic effect and improved anticancer efficacy, thereby encouraging the inclusion of these AIFCM as part of effective armamentarium in fighting intractable cancers. Finally, we present the challenges and future perspectives of AIFCM combination therapy as a feasible and promising strategy for the optimization of cancer treatment and better clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.